ReviewParasite epidemiology and control2026
Evaluating antiviral candidates for dengue virus infection: A review.
Review in Parasite epidemiology and control, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dengue virus (DENV) infection poses a significant global health threat, affecting millions worldwide. The virus is transmitted through the bite of infected mosquitoes, leading to a range of symptoms from mild fever to severe dengue hemorrhagic fever and dengue shock syndrome. Effective treatment strategies are urgently needed to combat this growing public health concern. Body: Several compounds, including chloroquine, favipiravir, ribavirin, ST-148, NITD-008, interferon β, curcumin, papaya leaf extracts, artemisinin, nanocurcumin, balapiravir, and andrographolide, exhibited antiviral activity against DENV in different cell lines. In vivo studies demonstrated the effectiveness of celgosivir, ST-148, NITD-008, and 2'- Conclusion: The findings suggest that some treatments may exacerbate disease symptoms while others, such as FCPLJ, exhibit potential for enhancing immune responses. This review highlights promising antiviral candidates for DENV treatment, emphasizing the need for further research to optimize efficacy and safety in human populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.